CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Operating expenses:
Research and development	$ 10,740	$ 2,370
General and administrative	3,757	613
Total operating expenses	14,497	2,983
Loss from operations	(14,497)	(2,983)
Other income (expense):
Interest expense	(305)
Change in fair value of warrant liability	(454)
Change in fair value of derivative liability	289	(3)
Change in fair value of contingent equity liability	(3,375)
Loss from equity method investment	(218)
Total other income (expense), net	(4,063)	(3)
Loss before provision for income taxes	(18,560)	(2,986)
Provision for income taxes	193
Net loss and comprehensive loss	(18,753)	(2,986)
Net loss attributable to non-controlling interests		35
Accretion of beneficial conversion feature on series A preferred shares	(4,000)
Net loss attributable to common shareholders of Biohaven Pharmaceutical Holding Company Ltd.	$ (22,753)	$ (2,951)
Net loss per share attributable to common share holders of Biohaven Pharmaceutical Holding Company Ltd.-basic and diluted	$ (1.74)	$ (0.25)
Weighted average common shares outstanding-basic and diluted	13,088,861	11,776,429